Dashboard
Manage Tickers

VTRSViatris Inc

Nasdaq viatris.com


$ 11.44 $ 0.16 (1.42 %)    

Monday, 09-Sep-2024 11:55:12 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 452.92 $ 0.39 (0.09 %)
DIA $ 409.97 $ 2.64 (0.65 %)
SPY $ 545.84 $ 1.17 (0.21 %)
TLT $ 99.94 $ 0.56 (0.56 %)
GLD $ 230.92 $ -0.34 (-0.15 %)
$ 11.27
$ 11.28
$ 11.43 x 2,380
$ 11.44 x 2,200
$ 11.27 - $ 11.45
$ 8.36 - $ 13.20
9,593,640
na
13.45B
$ 0.83
nm
TBD
na
na ($ 0.04)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 02-28-2024 12-31-2023 10-K
4 11-07-2023 09-30-2023 10-Q
5 08-07-2023 06-30-2023 10-Q
6 05-08-2023 03-31-2023 10-Q
7 02-27-2023 12-31-2022 10-K
8 11-07-2022 09-30-2022 10-Q
9 08-08-2022 06-30-2022 10-Q
10 05-09-2022 03-31-2022 10-Q
11 02-28-2022 12-31-2021 10-K
12 11-08-2021 09-30-2021 10-Q
13 08-09-2021 06-30-2021 10-Q
14 05-10-2021 03-31-2021 10-Q
15 03-01-2021 12-31-2020 10-K
16 11-10-2020 09-27-2020 10-Q
17 08-12-2020 06-28-2020 10-Q
18 05-12-2020 03-29-2020 10-Q
19 05-07-2020 12-31-2019 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

jp-morgan-shows-most-interest-in-teva-organon-as-specialty-pharma-sector-exhibits-signs-of-stability
JP Morgan Shows Most Interest In Teva, Org...
09/06/2024 17:46:07

JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva,...

shortage-relief-more-takedas-vyvanse-for-adhd-on-the-way-as-us-ramps-up-production
Shortage Relief: More Takeda's Vyvanse For...
09/06/2024 13:46:26

Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and gl...

viatris-says-late-breaking-oral-presentation-shows-that-cenerimod-for-systemic-lupus-erythematosus-in-japanese-patients-can-be-considered-safe-and-well-tolerated
Viatris Says Late-breaking Oral Presentati...
08/23/2024 11:00:58

The ACT-333441 study was accepted as a late-breaking abstract and was presented during an oral presentation at the 26th Asia-Pa...

10-health-care-stocks-with-whale-alerts-in-todays-session
10 Health Care Stocks With Whale Alerts In...
08/15/2024 17:35:23

us-drugmaker-viatris-q2-earnings-edge-out-analysts-expectation-on-strong-demand-for-branded-and-generic-drugs
US Drugmaker Viatris Q2 Earnings Edge Out ...
08/08/2024 17:54:07

Viatris reports Q2 revenue of $3.78 billion, with strong growth in Greater China and new product launches driving results. Adju...

viatris-expects-2024-adjusted-eps-of-258-273-versus-prior-guidance-of-266-281-and-consensus-of-273
Viatris Expects 2024 Adjusted EPS Of $2.58...
08/08/2024 11:13:53

viatris-expects-2024-sales-of-146b-151b-versus-prior-guidance-of-1498b-1548b-and-consensus-of-14956b
Viatris Expects 2024 Sales Of $14.6B-$15.1...
08/08/2024 11:12:46

viatris-q2-2024-adj-eps-069-beats-068-estimate-sales-3786b-beat-3777b-estimate
Viatris Q2 2024 Adj. EPS $0.69 Beats $0.68...
08/08/2024 11:01:21

novartis-and-viatris-sued-over-unlawful-use-of-hela-cells-used-for-cancer-treatment-drugs
Novartis And Viatris Sued Over Unlawful Us...
08/06/2024 17:48:49

Henrietta Lacks' family sues Novartis and Viatris for profiting from her HeLa cells without consent. The lawsuit seeks prof...

warner-bros-discovery--coinbase-are-among-10-large-cap-stocks-that--shined-most-last-week-july-14-july-20-are-the-others-in-your-portfolio
Warner Bros. Discovery & Coinbase Are Amon...
07/21/2024 13:57:03

Top performers last week: $WBD up 18.28%, $MSTR up 16.74%, $DHI up 12.91%, $COIN up 12.39%, $OQL up 7.89%, $UNH up 7.84%, $STT ...

jefferies-reinstates-buy-on-viatris-announces-15-price-target
Jefferies Reinstates Buy on Viatris, Annou...
07/19/2024 12:48:54

Jefferies analyst Glen Santangelo reinstates Viatris (NASDAQ:VTRS) with a Buy and announces $15 price target.

Core News & Articles
Reported Thursday, Calliditas Therapeutics...
07/05/2024 06:42:47

The clinical trial is a bridging study requiring a limited number of Japanese patients to participate in a study similar in des...

viatris-completes-all-previously-announced-divestitures-with-the-closing-of-its-over-the-counter-business-divestiture
Viatris Completes All Previously Announced...
07/03/2024 12:33:15

Achievement of This Major Milestone Further Simplifies and Strengthens the Company and Positions Viatris to Achieve its Key Pri...

viatris-announced-that-the-antitrust-division-of-us-department-of-justice-has-advised-that-it-no-longer-considers-mylan-and-its-former-president-rajiv-malik-a-subject-of-its-antitrust-investigation-in-the-generic-drug-industry
Viatris Announced That The Antitrust Divis...
07/02/2024 11:41:01

The Civil Division of the DOJ has also informed the Company that it does not expect to take any further actions in connection w...

peering-into-viatriss-recent-short-interest
Peering Into Viatris's Recent Short Interest
05/27/2024 15:15:22

weak-sales-from-lipitor-norvasc-hurt-viatris-q1-earnings-lowers-annual-forecast
Weak Sales From Lipitor, Norvasc Hurt Viat...
05/09/2024 18:23:13

Viatris reports Q1 EPS in line with consensus at $0.67, with sales slightly missing expectations at $3.66 billion. Strong growt...

stocks-rebound-as-rising-jobless-claims-sustain-rate-cut-hopes-dollar-falls-gold-rallies-whats-driving-markets-thursday
Stocks Rebound As Rising Jobless Claims Su...
05/09/2024 16:42:34

Wall Street is seeing a day of gains as all major indices traded in the green around noon in New York, driven by a surprising u...

viatris-expects-2024-adjusted-eps-of-266-281-versus-prior-guidance-of-270-285-and-consensus-of-274
Viatris Expects 2024 Adjusted EPS Of $2.66...
05/09/2024 11:06:22

viatris-expects-2024-revenues-of-1498b-1548b-versus-consensus-of-1519b-and-prior-guidance-of-1525b-1575b
Viatris Expects 2024 Revenues Of $14.98B-$...
05/09/2024 11:05:24

viatris-q1-2024-gaap-eps-067-inline-sales-3663b-miss-3691b-estimate
Viatris Q1 2024 GAAP EPS $0.67, Inline, Sa...
05/09/2024 11:01:57

Viatris (NASDAQ:VTRS) reported quarterly earnings of $0.67 per share which met the analyst consensus estimate. This is a 12.99 ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION